Literature DB >> 23788550

Draft Genome Sequence of Streptomyces viridochromogenes Strain Tu57, Producer of Avilamycin.

Björn A Grüning1, Anika Erxleben, Anna Hähnlein, Stefan Günther.   

Abstract

Here we present the draft genome sequence of Streptomyces viridochromogenes Tü57. This strain is a producer of avilamycin A, an oligosaccharide antibiotic from the orthosomycin group, which is active against Gram-positive bacteria.

Entities:  

Year:  2013        PMID: 23788550      PMCID: PMC3707599          DOI: 10.1128/genomeA.00384-13

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

Streptomyces viridochromogenes strain Tü57 is a producer of avilamycin A, a potent antibiotic against Gram-positive pathogenic bacteria. Avilamycin is an oligosaccharide antibiotic which belongs to the orthosomycin group (1). Members of this group show high antibacterial activity against glycopeptide-resistant enterococci, penicillin-resistant streptococci, and methicillin-resistant staphylococci (2–4). Avilamycin A consists of a hepta-saccharide side chain and a polyketide-derived dichloroisoeverninic acid as aglycone. Several genes from the secondary metabolite gene cluster which encodes the biosynthesis of avilamycin A have been characterized previously (5–7). The whole-genome shotgun sequence was determined by Roche/454 GS FLX titanium pyrosequencing technology (8). Generation of a paired-end library consisting of 855,621 reads was performed, which corresponds to 17-fold coverage. All reads were assembled using Newbler 2.5.3, and 379 contigs were obtained. The genome of Streptomyces viridochromogenes Tü57 is composed of 9.7 Mbp, with an average G+C content of 71%. For the analysis of the S. viridochromogenes Tü57 genome, open reading frames were predicted by Glimmer3 using a specific Streptomyces training set (9). Genome annotation was performed by applying an in-house-developed Galaxy-based automatic genome annotation pipeline for Streptomycetes. In order to determine putative secondary metabolites, prediction of gene clusters was performed using antiSMASH (10). The analysis revealed that 846 genes belong to 33 secondary metabolite gene clusters. From those, we identified two polyketide synthase type I (PKSI) gene clusters, one PKSII, two PKSIII, 9 nonribosomal peptide synthetase (NRPS), two hybrid NRPS-PKSI, three terpene, and 14 other gene clusters. Furthermore, the analysis of nontranslating genes predicted at least 68 tRNAs and 1 tmRNA on the genome (11, 12).

Nucleotide sequence accession number.

This whole-genome shotgun project has been deposited at DDBJ/EMBL/GenBank under the accession number AMLP00000000. The version described in this paper is the first version.
  12 in total

1.  ARAGORN, a program to detect tRNA genes and tmRNA genes in nucleotide sequences.

Authors:  Dean Laslett; Bjorn Canback
Journal:  Nucleic Acids Res       Date:  2004-01-02       Impact factor: 16.971

2.  Identifying bacterial genes and endosymbiont DNA with Glimmer.

Authors:  Arthur L Delcher; Kirsten A Bratke; Edwin C Powers; Steven L Salzberg
Journal:  Bioinformatics       Date:  2007-01-19       Impact factor: 6.937

3.  tRNAscan-SE: a program for improved detection of transfer RNA genes in genomic sequence.

Authors:  T M Lowe; S R Eddy
Journal:  Nucleic Acids Res       Date:  1997-03-01       Impact factor: 16.971

4.  Biosynthesis of the orthosomycin antibiotic avilamycin A: deductions from the molecular analysis of the avi biosynthetic gene cluster of Streptomyces viridochromogenes Tü57 and production of new antibiotics.

Authors:  G Weitnauer; A Mühlenweg; A Trefzer; D Hoffmeister; R D Süssmuth; G Jung; K Welzel; A Vente; U Girreser; A Bechthold
Journal:  Chem Biol       Date:  2001-06

5.  [Avilamycin].

Authors:  F Buzzetti; F Eisenberg; H N Grant; W Keller-Schierlein; W Voser; H Zähner
Journal:  Experientia       Date:  1968-04-15

6.  In vitro activities of SCH27899 alone and in combination with 17 other antimicrobial agents.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

7.  Evernimicin (SCH27899) inhibits both translation and 50S ribosomal subunit formation in Staphylococcus aureus cells.

Authors:  W S Champney; C L Tober
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

8.  Cloning of an avilamycin biosynthetic gene cluster from Streptomyces viridochromogenes Tü57.

Authors:  S Gaisser; A Trefzer; S Stockert; A Kirschning; A Bechthold
Journal:  J Bacteriol       Date:  1997-10       Impact factor: 3.490

Review 9.  Pharmacologic and bacteriologic properties of SCH-27899 (Ziracin), an investigational antibiotic from the everninomicin family.

Authors:  D R Foster; M J Rybak
Journal:  Pharmacotherapy       Date:  1999-10       Impact factor: 4.705

10.  antiSMASH: rapid identification, annotation and analysis of secondary metabolite biosynthesis gene clusters in bacterial and fungal genome sequences.

Authors:  Marnix H Medema; Kai Blin; Peter Cimermancic; Victor de Jager; Piotr Zakrzewski; Michael A Fischbach; Tilmann Weber; Eriko Takano; Rainer Breitling
Journal:  Nucleic Acids Res       Date:  2011-06-14       Impact factor: 16.971

View more
  3 in total

Review 1.  Using bacterial genomes and essential genes for the development of new antibiotics.

Authors:  Francisco R Fields; Shaun W Lee; Michael J McConnell
Journal:  Biochem Pharmacol       Date:  2016-12-08       Impact factor: 5.858

2.  Wide Distribution of Foxicin Biosynthetic Gene Clusters in Streptomyces Strains - An Unusual Secondary Metabolite with Various Properties.

Authors:  Anja Greule; Marija Marolt; Denise Deubel; Iris Peintner; Songya Zhang; Claudia Jessen-Trefzer; Christian De Ford; Sabrina Burschel; Shu-Ming Li; Thorsten Friedrich; Irmgard Merfort; Steffen Lüdeke; Philippe Bisel; Michael Müller; Thomas Paululat; Andreas Bechthold
Journal:  Front Microbiol       Date:  2017-02-21       Impact factor: 5.640

3.  Recently published Streptomyces genome sequences.

Authors:  James Harrison; David J Studholme
Journal:  Microb Biotechnol       Date:  2014-09       Impact factor: 5.813

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.